Feasibility Of continuous non-invasive blood pressure measurement in cardiac Resynchronization ThErapy
Completed
- Conditions
- failure of pumpfunction of the heartHeart failure10019280
- Registration Number
- NL-OMON36535
- Lead Sponsor
- Sint Antonius Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1) End stage heart failure with NYHA class II, III or IV despite optimal medical treatment 2) QRS duration > 120msec for patients in NYHA class III or IV, QRS duration > 150msec for patients in NYHA class II
3) Left ventricular ejection fraction < 35%
Exclusion Criteria
1) Age < 18 years
2) Planned revascularization therapy or reparative cardiac surgery <6 months
3) Expected heart transplantation <1 year
4) Severe heart failure with short (<6 months) life expectancy
5) Chronic atrial fibrillation
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Difference of 3.5% in left ventricular ejection fraction between both<br /><br>strategies measured by 3-D echocardiography.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Changes in NYHA classification, NT-pro-BNP, 6-MWT, and QOL score assessed by the<br /><br>Minnesota Living with Heart Failure questionnaire, LVEDD, LVESD, LVEDV and<br /><br>LVESV, MR, incidence of ventriculartachycardia<br /><br>or fibrillation (VT, VF), ICD delivered antitachycardia pacing (ATP) and<br /><br>shocks, days of hospitalization<br /><br>for or associated with worsening HF and mortality of any cause.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie blood pressure variability in heart failure patients undergoing cardiac resynchronization therapy?
How does continuous non-invasive blood pressure monitoring compare to standard invasive methods in predicting outcomes for heart failure patients with cardiac resynchronization therapy?
Which biomarkers are associated with improved response to cardiac resynchronization therapy in patients with pump function failure of the heart?
What are the potential adverse events associated with continuous non-invasive blood pressure monitoring in cardiac resynchronization therapy and how can they be managed?
Are there any combination approaches or competitor devices that enhance the feasibility of blood pressure monitoring in heart failure patients receiving cardiac resynchronization therapy?